Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agilon Health (AGL) Shares Outstanding (Weighted Average) (2020 - 2025)

Agilon Health (AGL) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $414.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 0.73% year-over-year to $414.0 million, compared with a TTM value of $414.0 million through Dec 2025, up 0.73%, and an annual FY2025 reading of $414.0 million, up 0.73% over the prior year.
  • Shares Outstanding (Weighted Average) was $414.0 million for Q4 2025 at Agilon Health, roughly flat from $414.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $414.5 million in Q3 2025 and bottomed at $325.7 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $401.8 million, with a median of $411.0 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) grew 23.43% in 2022, then decreased 1.02% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $372.9 million in 2021, then rose by 9.44% to $408.2 million in 2022, then rose by 0.19% to $408.9 million in 2023, then increased by 0.5% to $411.0 million in 2024, then grew by 0.73% to $414.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for AGL at $414.0 million in Q4 2025, $414.5 million in Q3 2025, and $413.8 million in Q2 2025.